By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

Alternative Quality Contract with Blue Cross Blue Shield of Massachusetts: A Model for ACOs?
The Future of Health Insurance
An Archipelago of Health Information Islands
Medicare’s Data Release Places More Power in Hands of Informed Medical Consumers
CBO: Private Insurers Better at Expenditure Growth Control than Medicare, Medicaid

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Invisalign for Adults: Is It Too Late to Straighten Your Teeth?
Dental health Specialties
February 24, 2026
roads are important for health
How Everyday Roads Create Lasting Health Consequences 
Health
February 24, 2026
How Balanced High-Protein Meals Fit Into Modern Wellness Routines
Uncategorized
February 18, 2026
ptsd treatment
The Ongoing Challenges of Living With PTSD
Mental Health Wellness
February 17, 2026

You Might also Like

under armour
BusinesseHealthMedical DevicesMobile HealthTechnologyWellness

Under Armour Leaps into Digital Health with MapMyFitness Acquisition

November 17, 2013

Health Care Online Marketing, Social Media and HIPAA: Google Hangout on Air

July 21, 2014
BusinessGlobal HealthcareNewsPolicy & LawPublic Health

The Truth About Healthcare Around the World

November 28, 2011
healthcare tweeting tips
BusinesseHealthSocial Media

Beyond the Buzz: 13 Unwritten Rules of Healthcare Tweeting

August 2, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?